Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v33-FR Version v31-EN
Language French English
Date Updated 2019-06-10 2019-06-10
Drug Identification Number 01927620 01927620
Brand name MYOCHRYSINE MYOCHRYSINE
Common or Proper name MYOCHRYSINE 10MG/ML LJ AMP5 MYOCHRYSINE 10MG/ML LJ AMP5
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients GOLD SODIUM THIOMALATE GOLD SODIUM THIOMALATE
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 5 AMPOULES 5 AMPOULES
ATC code M01CB M01CB
ATC description SPECIFIC ANTIRHEUMATIC AGENTS SPECIFIC ANTIRHEUMATIC AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2018-04-04 2018-04-04
Actual start date 2018-04-04 2018-04-04
Estimated end date 2019-09-30 2019-09-30
Actual end date 2019-06-04 2019-06-10
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. Discontinuation
Health Canada comments